Andrew Levin, M.D., Ph.D.

Andrew is a Co-Founder of Climb Bio (formerly Eliem Therapeutics) and served as Eliem’s Chief Executive Officer and Chairman of the Board of Directors. Andrew spearheads drug discovery efforts at RA Capital Management, L.P. that have led to the formation of several companies and serves as a Managing Director on the Investment Team. Previously, Andrew was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative.

Dr. Levin holds a bachelor of science in mechanical engineering from Princeton University, a doctorate in biomedical engineering from the Massachusetts Institute of Technology and a medical degree from Harvard Medical School.